Italia markets open in 2 hours 51 minutes

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,9700-0,1614 (-3,91%)
Alla chiusura: 03:02PM GMT

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Settore/i
Settore
Impiegati a tempo pieno124

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Nancy A. Simonian M.D.Pres, CEO & Director939,4kN/D1961
Dr. Richard A. Young Ph.D.Scientific Founder, Member of Scientific Advisory Board & Director50kN/D1954
Mr. Jason HaasChief Financial Officer457,22kN/D1968
Dr. David A. Roth M.D.Chief Medical Officer668,12kN/D1963
Dr. James E. Bradner M.D.FounderN/DN/D1972
Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/DN/DN/D
Dr. Eric R. Olson Ph.D.Chief Scientific OfficerN/DN/D1958
Courtney SolbergMang. of Corp. Communications and Investor RelationsN/DN/DN/D
Mr. Gerald E. Quirk Esq., J.D.Chief Legal OfficerN/DN/D1968
Dr. Christian C. Fritz Ph.D.Head of BiologyN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Syros Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.